Sage (Salvia officinalis) is a non-toxic European herb that has a tradition of treatment for cognitive deficits dating back to the Middle Ages.1 Sage extracts have been shown to inhibit acetyl-cholinesterase. They also possess anti-oxidant, anti-inflammatory, and estrogenic properties. Clinical studies have demonstrated sage’s cognitive enhancing effects for primary, secondary, and working memory2,3 when administered in an acute regime in healthy young and elderly volunteers. And, chronic administration has been shown to reduce cognitive decline in patients with Alzeihmer’s disease4.

Clinical studiesScholey et al3 demonstrated a clear benefit in key cognitive performance within 1 hour of administering 167mg and 333mg of Sibelius:Sage (“sage”) extract to 20 healthy elderly volunteers (65-90 years).

Figure 1. Effects of a standardized extract of S. officinalis (167, 333, 666, 1332 mg) and placebo on cognitive factors derived from Cognitive Drug Research computerized assessment battery. Mean change from baseline scores are shown for a) secondary memory and b) accuracy of attention.

Sibelius:Sage is a clinically tested natural supplement for the support of cognitive health

20a

0

-20

-40

-60

-801h 2.5h 4h 6h

3b

2

1

0

-2

-1

1h 2.5h 4h 6h-3

*****

* * *********

**

**** ****

PLACEBO 167 mg 333 mg 666 mg 1332 mg

*p<0.05 **p<0.01 ***p<0.001 ****p<0.001 *****p<0.005

Clinical studies cont...• Dose Response: Clear dose response

effect, with statistical significance consistently showing for 333 mg dose

• Effect of Treatment: Strong statistically significant effect over baseline at all assessment time periods for 333 mg dose, for Secondary Memory (recognition and recall tasks)

• Effect of Treatment: Statistically significant effect over baseline at 1, 4 and 6 hr assessment time periods (very strong at 4 & 6 hrs) for Accuracy of Attention (accuracy in choice and vigilance tasks)

• Effect of Treatment: Statistically significant effect over baseline at 1 hr assessment period for Working Memory (spatial and numeric memory – accuracy and speed of reaction)

In vivo studiesHowever, the challenge has been to standardize the cognitive benefits of sage with the multiple species, sources, and extraction procedures for the potent botanical. Using Sibelius’ Chronoscreen™, we have been able to demonstrate that there is a significant difference in biological activity of Sibelius:Sage (used in the Scholey 2008 study) over that of other sage sources and extraction procedures. (Sibelius internal data, see below)

CLS Extension - Chronological Life Extension is measured on Sibelius’ patented ChronoscreenTM technology, and allows for the identification of biologically active natural products in the model organism Caenorhabditis elegans.

Key benefits1. Clinically tested extract3

2. Patent pending5

3. GRAS listed4. Available as raw extract or formulated

product

Contact UK

Sibelius Natural Products26 Beaumont Street, Oxford, OX1 2NP, UK

T +44(0)1865518910

info@sibeliusnaturalproducts.com

www.sibeliusnaturalproducts.com

Company No. 6949779 VAT No. 114469617

S. officinalis(Sibelius:Sage)

CLS

ext

ensi

on (%

)

S. officinalis(UK Source A)

S. officinalis(UK Source B)

S. officinalis(UK Spain)

15

10

5

0

-5

-10

-15

Citations

1 Kennedy, D.O, et al. (2006) “The Psychopharmacology of European Herbs Cognitive Enhancing Properties” Current Pharmaceutical Design, 12:2613-4623.

2 Kennedy, D.O et al (2006) “Effects of Cholinesteras Inhibiting Sage (Salvia officinalis) on Mood, Anxiety and Performance on a Psychological Stressor Batter” Neuropsychopharmacology, 31: 845-852.

3 Scholey A.B, et al. (2008) “An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers” Psychopharmacology, 198:127-139.

4 Akhondzadeh, S. et al. (2003) “Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer’s disease: a double blind randomized and placebo-controlled trial” J of Clinical Pharmacy and Therapeutics, 28:53-59.

5 Sibelius Sage patent pending (WO 2017/129987 A1), published August 3, 2017